Legal Representation
Attorney
Maryann E. Licciardi
USPTO Deadlines
Next Deadline
1070 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-21)
Due Date
June 21, 2028
Grace Period Ends
December 21, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
29 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 25, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Oct 2, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Oct 2, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 21, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jun 21, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 21, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 5, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 5, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 16, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 3, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 3, 2022 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 3, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 3, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 3, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 25, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 25, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 25, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 25, 2022 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Feb 25, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 25, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jan 23, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 4, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jan 4, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Dec 11, 2021 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Dec 10, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 7, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 3, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jul 30, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 29, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Protein expression systems, namely, human proteins for life science and medical research
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Biological preparations for pharmaceutical and veterinary purposes, in particular biological preparations developed from biological cells for the treatment of cancer, inflammatory disease and infectious disease; biological diagnostic preparations for medical and veterinary use; cells for medical use; viral vaccines; vaccine adjuvants
First Use Anywhere:
0
First Use in Commerce:
0
Class 040
Custom manufacturing services of drugs; custom manufacture of pharmaceuticals; custom manufacture of proteins and vaccines and gene therapy with the aid of biological cells, including manufacture of biological active substances
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Research and development in the fields of bacteriology, cellular engineering, cytology, antibodies, glycomics, chemistry, microorganisms, proteins, immunology, biological therapeutics, nutraceuticals and gene expression systems; scientific research and genome synthesis in the nature of genome amplification services for others; scientific and technological research services and research services in the fields of genetics, epigenetics and expression analysis; research and development in the field of biotechnology, namely, conducting protein expression; scientific and industrial research, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures and expression systems; research and development services relating to vaccines; scientific research in the field of genetics and genetic engineering; research in the field of gene therapy
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Medical services relating to the removal, treatment and processing of human cells
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
DIRECTED LUCK
Classification
International Classes
001
005
040
042
044